|
 Investing in China's pharmaceutical industry is the second edition of a paper published by PricewaterhouseCoopers looking into the current pharmaceutical market conditions in China. The report covers various subjects that are considered to be of concern to the pharmaceutical industry and/or investors in the pharmaceutical industry in China.
It builds on the foundation set in the first report, published in 2006. The pharmaceutical/life sciences landscape is changing fast in China and this new edition reviews, updates and expands on the following key areas: traditional Chinese medicine, China's over the counter market, medical devices, contract research organisations, contract manufacturing organisations, development of innovation, tax incentives in China, bribery and corruption in sales and marketing, challenge of drug pricing, distribution systems, intellectual property protection, market consolidation and financial impacts of investments.
Get your copy here
Read more by downloading our Investing in China's pharmaceutical industry (pdf file, 955KB) for your reference.
|
